Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene belongs to the family of P-type cation transport ATPases, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The catalytic subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes an alpha 1 subunit. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]
ATP1A1 (ATPase Na+/K+ Transporting Subunit Alpha 1) is a Protein Coding gene. Diseases associated with ATP1A1 include Charcot-Marie-Tooth Disease, Axonal, Type 2Dd and Hypomagnesemia, Seizures, And Mental Retardation 2. Among its related pathways are Antiarrhythmic Pathway, Pharmacodynamics and cGMP-PKG signaling pathway. Gene Ontology (GO) annotations related to this gene include nucleotide binding and protein domain specific binding. An important paralog of this gene is ATP1A3.
The Na+/K+ ATPase is a membrane protein that is composed of two subunits - alpha and beta. The pump maintains an essential electrochemical gradient within cells through the active transport of sodium (Na+) and potassium (K+) ions.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000166 | nucleotide binding | IEA | -- |
GO:0005391 | sodium:potassium-exchanging ATPase activity | IBA,ISS | -- |
GO:0005515 | protein binding | IPI | 11027149 |
GO:0005524 | ATP binding | ISS | -- |
GO:0008556 | potassium-transporting ATPase activity | IEA | -- |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005768 | endosome | IEA | -- |
GO:0005783 | endoplasmic reticulum | ISS | -- |
GO:0005794 | Golgi apparatus | ISS | -- |
GO:0005886 | plasma membrane | TAS | -- |
GO:0005890 | sodium:potassium-exchanging ATPase complex | TAS,ISS | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Cardiac conduction |
.39
|
|
2 | Aldosterone synthesis and secretion | ||
3 | Salivary secretion | ||
4 | cGMP-PKG signaling pathway | ||
5 | Cytoskeletal Signaling |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0002026 | regulation of the force of heart contraction | IEA | -- |
GO:0002028 | regulation of sodium ion transport | ISS | -- |
GO:0006811 | ion transport | IEA | -- |
GO:0006813 | potassium ion transport | IEA | -- |
GO:0006814 | sodium ion transport | IEA | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Ouabain | Approved | Pharma | Target, inhibitor, binder | Na+/K+ ATPase inhibitor | 0 | |
Digoxin | Approved | Pharma | Target, inhibitor | Na+/K+ ATPase inhibitor | 187 | |
Acetyldigitoxin | Approved | Pharma | Target, inhibitor | 0 | ||
Almitrine | Approved | Pharma | Target, binder | 3 | ||
Bepridil | Approved, Withdrawn | Pharma | Target, inhibitor, blocker | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
ADP |
|
58-64-0 |
|
|||
sodium |
|
7440-23-5 |
|
Compound | Action | Cas Number |
---|---|---|
Digoxin | Na+/K+ ATPase inhibitor | 20830-75-5 |
Lithium carbonate | Mood stabilizer; inhibits Na+/K+ ATPase pump activity | 554-13-2 |
Ouabain | Na+/K+ ATPase inhibitor | 630-60-4 |
Rostafuroxin | Na+/K+ ATPase modulator; antihypertensive agent | 156722-18-8 |
Compound | Action | Cas Number |
---|---|---|
ARL 67156 trisodium salt | ecto-ATPase inhibitor | 1021868-83-6 |
Cyclopiazonic acid | 18172-33-3 | |
Enterostatin | 117830-79-2 | |
Istaroxime | Na+/K+ ATPase inhibitor | 203737-93-3 |
Istaroxime hydrochloride | Inhibitor of Na+/K+ ATPase | 374559-48-5 |
K 858 | 72926-24-0 | |
Lansoprazole sodium | PPI/cytochrome P450 inhibitor | 226904-00-3 |
Lithium carbonate | 554-13-2 | |
ML 240 | 1346527-98-7 | |
MYK-461 | inhibits adenosine triphosphatase activity | |
Ochratoxin A | 303-47-9 | |
Paprotrain | 57046-73-8 | |
Paxilline | 57186-25-1 | |
POM 1 | 12141-67-2 | |
PSB 06126 | 1052089-16-3 | |
PSB 069 | 78510-31-3 | |
SCH 28080 | 76081-98-6 | |
Thapsigargin | 67526-95-8 |
ExUns: | 1 | ^ | 2 | ^ | 3a | · | 3b | ^ | 4 | ^ | 5 | ^ | 6a | · | 6b | ^ | 7 | ^ | 8 | ^ | 9a | · | 9b | ^ | 10a | · | 10b | ^ | 11a | · | 11b | · | 11c | ^ | 12a | · | 12b | ^ | 13a | · | 13b | ^ | 14 | ^ | 15a | · | 15b | ^ | 16a | · | 16b | · |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP2: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP3: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP4: | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
SP5: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP6: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP7: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP8: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP9: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP10: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP11: |
ExUns: | 16c | ^ | 17 | ^ | 18 | ^ | 19 | ^ | 20 | ^ | 21a | · | 21b | ^ | 22 | ^ | 23a | · | 23b | ^ | 24 | ^ | 25 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | |||||||||||||||||||||
SP2: | - | - | - | - | - | - | - | - | |||||||||||||||
SP3: | |||||||||||||||||||||||
SP4: | |||||||||||||||||||||||
SP5: | |||||||||||||||||||||||
SP6: | |||||||||||||||||||||||
SP7: | |||||||||||||||||||||||
SP8: | |||||||||||||||||||||||
SP9: | |||||||||||||||||||||||
SP10: | |||||||||||||||||||||||
SP11: |
This gene was present in the common ancestor of animals and fungi.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | ATP1A1 30 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | mdo-mir-7282 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | -- 31 |
|
OneToMany | |
-- 31 |
|
OneToMany | |||
-- 31 |
|
OneToMany | |||
-- 31 |
|
OneToMany | |||
Dog (Canis familiaris) |
Mammalia | ATP1A1 30 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | ATP1A1 30 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Atp1a1 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Atp1a1 30 |
|
||
Chicken (Gallus gallus) |
Aves | ATP1A1 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | ATP1A1 31 |
|
OneToOne | |
Tropical Clawed Frog (Silurana tropicalis) |
Amphibia | atp1a1 30 |
|
||
MGC76277 30 |
|
||||
Zebrafish (Danio rerio) |
Actinopterygii | atp1a1b 31 |
|
OneToMany | |
atp1a1a.5 31 |
|
OneToMany | |||
atp1a1a.2 31 |
|
OneToMany | |||
atp1a1a.1 30 31 |
|
OneToMany | |||
Fruit Fly (Drosophila melanogaster) |
Insecta | Atpalpha 31 32 |
|
OneToMany | |
CG17923 32 |
|
|
|||
CG3701 32 |
|
|
|||
Worm (Caenorhabditis elegans) |
Secernentea | eat-6 31 32 |
|
OneToMany | |
C02E7.1 32 |
|
|
|||
Y105E8A.12 32 |
|
|
|||
Baker's yeast (Saccharomyces cerevisiae) |
Saccharomycetes | ENA5 31 |
|
ManyToMany | |
ENA1 31 |
|
ManyToMany | |||
ENA2 31 |
|
ManyToMany | |||
Sea Squirt (Ciona savignyi) |
Ascidiacea | -- 31 |
|
OneToMany | |
Sea Vase (Ciona intestinalis) |
Ascidiacea | Cin.5338 30 |
|
SNP ID | Clinical significance and condition | Chr 01 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
872433 | Likely Benign: not provided | 116,398,991(+) |
C/T NM_000701.8(ATP1A1):c.2355C>T (p.Pro785=) |
SYNONYMOUS | |
931627 | Uncertain Significance: Hypomagnesemia, seizures, and mental retardation 2 | 116,399,513(+) |
C/T NM_000701.8(ATP1A1):c.2542C>T (p.Arg848Trp) |
MISSENSE | |
931678 | Uncertain Significance: Hypomagnesemia, seizures, and mental retardation 2 | 116,374,250(+) |
T/A NM_000701.8(ATP1A1):c.12+727T>A |
INTRON | |
992402 | Uncertain Significance: Hypomagnesemia, seizures, and mental retardation 2 | 116,396,627(+) |
C/G NM_000701.8(ATP1A1):c.1866C>G (p.Ile622Met) |
MISSENSE | |
995868 | Likely Pathogenic: Charcot-marie-tooth disease, axonal, type 2DD | 116,401,219(+) |
CTGTAAGACCAG/C NM_000701.8(ATP1A1):c.2809_2819del (p.Cys937fs) |
FRAMESHIFT |
Disorder | Aliases | PubMed IDs |
---|---|---|
charcot-marie-tooth disease, axonal, type 2dd |
|
|
hypomagnesemia, seizures, and mental retardation 2 |
|
|
charcot-marie-tooth disease |
|
|
tooth disease |
|
|
parastremmatic dwarfism |
|
|